文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

靶向红系细胞来源的天冬酰胺抑制镰状细胞病同种免疫

Targeting erythroid cell-derived asparagine inhibits alloimmunization in sickle cell disease.
PubMed 文献 · Blood Adv · 2026-01-01

该研究在镰状细胞病(SCD)小鼠中发现血浆和红系细胞内L-天冬酰胺(Asn)水平升高,循环红系细胞贡献血浆Asn。线粒体阳性(Mito+)红系细胞增多与Asn合成增强相关。耗竭Asn可减少SCD小鼠红细胞同种免疫,并抑制浆细胞分化而保留静息B细胞;体外实验显示Asn促进人B细胞分化。提示Mito+红系细胞Asn-SFK轴调控同种免疫。

要点

  • SCD小鼠血浆和红系细胞Asn水平升高,输血实验证实红系细胞贡献血浆Asn。
  • ASNase耗竭Asn减少SCD小鼠红细胞同种免疫,并抑制浆细胞分化。
  • Asn补充促进人B细胞分化,SCD患者细胞效应更明显。

核心结论

  • Mito+红系细胞来源的Asn可能通过SFK信号调控SCD中的红细胞同种免疫。
  • 调控Asn-SFK轴可能为未来治疗探索提供基础。

研究设计与样本

  • 研究采用SCD小鼠模型、相互输血实验及体外人类B细胞实验。
  • 原文未报告样本量、具体分组数或统计学阈值。

主要发现

  • SCD小鼠血浆和红系细胞中Asn水平升高。
  • 正常红细胞输注至SCD小鼠降低血浆Asn,SCD红系细胞输注至野生型小鼠升高血浆Asn。
  • SCD中Mito+红系细胞增多与Asn合成增强相关。
  • ASNase减少SCD小鼠红细胞同种免疫,作用强于对照小鼠;外源Asn增加野生型小鼠同种免疫。
  • ASNase抑制浆细胞分化而保留静息B细胞,并降低SCD中SFK活化。

关键数值与推荐

  • 原文未报告具体数值阈值、比例、剂量或P值。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Red blood cell (RBC) transfusions remain a life-saving therapy for patients with sickle cell disease (SCD), yet their safety and efficacy are limited by a high incidence of alloimmunization. Emerging evidence suggests that metabolites, including amino acids, can influence humoral immune responses. Here, we found that levels of l-asparagine (Asn), a metabolite previously implicated in immunoregulation, are increased in both plasma and erythroid cells in SCD mice. Reciprocal transfusion indicated that circulating erythroid cells contribute to plasma Asn levels, as transfusion of normal RBCs into SCD mice reduced plasma Asn, whereas transfusion of SCD erythroid cells into wild-type mice increased plasma Asn. We further observed that increased mitochondria-positive (Mito+) erythroid cells in SCD were associated with enhanced Asn synthesis. Functionally, depletion of Asn using asparaginase (ASNase) reduced RBC alloimmunization in SCD mice, albeit more strongly than in control mice, whereas exogenous Asn administration increased alloimmunization in wild-type mice. In SCD mice, treatment with ASNase was associated with inhibition of plasma cell differentiation while sparing resting B cells. In vitro studies revealed that ASNase inhibited, whereas Asn supplementation promoted, human B-cell differentiation, with a more pronounced effect in cells from patients with SCD. ASNase treatment was also associated with reducing Src family kinase (SFK) activation in SCD, suggesting a potential link between Asn and SCD B-cell signaling. Together, these findings point to a potential role for Mito+ erythroid cell Asn-SFK axis in regulating RBC alloimmunization in SCD. Modulation of this pathway may provide a basis for future therapeutic exploration.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dou K, Su S, Bao W, et al. Targeting erythroid cell-derived asparagine inhibits alloimmunization in sickle cell disease. Blood Adv. 2026. PMID: 41995734. doi:10.1182/bloodadvances.2026020233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。